Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co., Ltd., is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products are mainly applied in the treatment of metabolism and digestive system, cardiovascular system, blood system, central nervous system, anti-infection, anti-tumor, vaccine and raw material and intermediates. Fosun Pharma provides medical diagnostic products including a real-time PCR detector, human papillomavirus assay kit and biofosun microorganism identification and susceptibility analysis system. The company's research and development unit concentrates on therapeutic areas of metabolism and digestive system, blood system, cardiovascular system and central nervous system. Fosun Pharma is headquartered in Shanghai, China.
Headquarters
China
Address
Building A, No. 1289 Yishan Road, Shanghai, 200233
Website
www.fosunpharma.com
Telephone
86 21 33987870
No of Employees
40,370
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600196 (SHA)
Revenue (2022)
$5.9B
-5.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-36%
(2022 vs 2021)
Market Cap*
$7.5B
Net Profit Margin (2022)
XYZ
-32.2%
(2022 vs 2021)
* As of and is in US$
Shanghai Fosun Pharmaceutical (Group) Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Therapy Area: Anti-Tumor and Immune Modulation: | Distribution and Retail | NG-Test CARBA5 |
| Han Li Kang (Rituximab Injection) | Medical Services | MyCare |
| Han Qu You (Trastuzumabiinjection) | Electronic Brachytherapy (eBx) System | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In February, Shanghai Fosun Pharmaceutical Industry Development Co and Fochon Pharmaceuticals secured approval from the National Medical Products Administration of the People’s Republic of China for a clinical trial of the FCN-338 tablet and FCN-647 tablet in combination to treat patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. |
| 2024 | Regulatory Approval | In January, Jinzhou Avanc Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for a new drug application of Famotidine Injection. |
| 2023 | Contracts/Agreements | In November, the company along with Wanbang Technology was approved by the National Medical Products Administration of China and the U.S. Food and Drug Administration for the clinical trial of the Investigational New Drug for the treatment of advanced head and neck squamous carcinoma, melanoma, and breast cancer, etc. |
Competitor Comparison
| Key Parameters | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Sinopharm Group Co Ltd | Sino Biopharmaceutical Ltd | Jiangsu Hengrui Medicine Co Ltd | Zhejiang Medicine Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | China |
| City | Shanghai | Shanghai | Hong Kong | Lianyungang | Shaoxing |
| State/Province | Shanghai | Shanghai | - | Jiangsu | Zhejiang |
| No. of Employees | 40,370 | 115,959 | 25,806 | 19,611 | 6,208 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wu Yifang | Chairman | Executive Board | 2020 | 54 |
| Guan Xiaohui | Vice Chairman | Executive Board | 2022 | 52 |
| Wen Deyong | Chief Executive Officer; Director | Executive Board | 2022 | 51 |
| Wang Kexin | Co Chairman | Executive Board | 2022 | 57 |
| Li Shengli | President | Senior Management | 2022 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer